Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
129 studies found for:    "Clear cell renal cell carcinoma"
Show Display Options
Rank Status Study
1 Recruiting A Phase 1, Dose-Escalation Trial of PT2385 Tablets In Patients With Advanced Clear Cell Renal Cell Carcinoma
Conditions: ccRCC;   RCC;   Kidney Cancer;   Clear Cell Renal Cell Carcinoma;   Renal Cell Carcinoma
Intervention: Drug: PT2385 Tablets
2 Active, not recruiting Study of Nivolumab (BMS-936558) vs. Everolimus in Pre-Treated Advanced or Metastatic Clear-cell Renal Cell Carcinoma (CheckMate 025)
Condition: Advanced or Metastatic (Medically or Surgically Unresectable) Clear-cell Renal Cell Carcinoma
Interventions: Biological: Nivolumab;   Drug: Everolimus
3 Unknown  Neoadjuvant Sunitinib Treatment for Metastatic Clear Cell Renal Cell Carcinoma (RCC)
Conditions: Clear Cell Renal Cell Carcinoma;   Metastasis
Intervention: Drug: Sunitinib
4 Terminated Sorafenib in Treating Patients With Locally Advanced or Metastatic Kidney Cancer
Conditions: Hereditary Clear Cell Renal Cell Carcinoma;   Kidney Cancer
Interventions: Drug: sorafenib tosylate;   Procedure: diffusion-weighted magnetic resonance imaging
5 Completed Tandutinib in Treating Patients Who Have Undergone Surgery for Metastatic Kidney Cancer
Conditions: Clear Cell Renal Cell Carcinoma;   Recurrent Renal Cell Cancer;   Stage IV Renal Cell Cancer
Interventions: Drug: tandutinib;   Other: laboratory biomarker analysis
6 Recruiting Pazopanib Hydrochloride and Bevacizumab in Treating Patients With Previously Untreated Metastatic Kidney Cancer
Conditions: Clear Cell Renal Cell Carcinoma;   Stage IV Renal Cell Cancer
Interventions: Drug: pazopanib hydrochloride;   Biological: bevacizumab;   Other: pharmacological study;   Other: laboratory biomarker analysis
7 Terminated
Has Results
Vandetanib to Treat Advanced Kidney Cancer
Condition: Advanced Clear Cell Renal Carcinoma
Intervention: Drug: vandetanib
8 Completed Effect of Sorafenib on ccRCC Uptake of Radiolabeled Bevacizumab or cG250
Condition: Clear Cell Renal Cell Carcinoma
Interventions: Drug: Sorafenib;   Drug: 111Indium-bevacizumab;   Drug: 111Indium-cG250
9 Recruiting AMG 172 First in Human Study in Patients With Kidney Cancer
Conditions: Renal Cell Adenocarcinoma;   Clear Cell Renal Carcinoma;   Clear Cell Renal Cell Carcinoma;   Renal Cell Carcinoma
Intervention: Drug: AMG 172
10 Completed
Has Results
Bevacizumab, Erlotinib, and Imatinib in the Treatment of Advanced Renal Cell Carcinoma
Condition: Clear Cell Renal Cell Carcinoma
Interventions: Drug: Bevacizumab;   Drug: Erlotinib;   Drug: Imatinib
11 Recruiting Phase II Study of Lutetium-177 Labeled Girentuximab in Patients With Advanced Renal Cancer
Condition: Metastatic Clear Cell Renal Cell Carcinoma
Intervention: Drug: Lu-177-DOTA-girentuximab
12 Recruiting Pazopanib Versus Temsirolimus in Poor-Risk Clear-Cell Renal Cell Carcinoma (RCC)
Condition: Kidney Cancer
Interventions: Drug: Pazopanib;   Drug: Temsirolimus;   Behavioral: Quality of Life Assessment;   Drug: Benadryl
13 Completed
Has Results
Pre-surgical Detection of Clear Cell Renal Cell Carcinoma (ccRCC) Using Radiolabeled G250-Antibody
Conditions: Renal Cell Carcinoma;   Kidney Cancer
Interventions: Drug: 124-Iodine-cG250 (124I-cG250);   Procedure: CT
14 Recruiting Biomarkers Before and After Nephrectomy of Locally Advanced or Metastatic Renal Cell Carcinoma Treated With Everolimus
Conditions: Clear-cell Renal Carcinoma;   Clear-cell Metastatic Renal Cell Carcinoma
Intervention: Drug: Everolimus
15 Active, not recruiting 1st-line Activity of Dovitinib and Correlation With Genetic Changes in RCC
Condition: Clear Cell Renal Cell Carcinoma
Intervention: Drug: Dovitinib
16 Not yet recruiting Value of Various Chemokines in the Detection and Follow up of RCC
Condition: Clear Cell Renal Cell Carcinoma
Intervention: Other: patients with renal cell carcinoma
17 Terminated
Has Results
AZD2171 in Treating Patients With Refractory Metastatic Kidney Cancer
Conditions: Clear Cell Renal Cell Carcinoma;   Recurrent Renal Cell Cancer;   Stage IV Renal Cell Cancer
Interventions: Drug: cediranib maleate;   Other: laboratory biomarker analysis
18 Active, not recruiting Fludarabine Phosphate, Low-Dose Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer
Conditions: Accelerated Phase Chronic Myelogenous Leukemia;   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   B-cell Chronic Lymphocytic Leukemia;   Childhood Acute Lymphoblastic Leukemia in Remission;   Childhood Acute Myeloid Leukemia in Remission;   Childhood Chronic Myelogenous Leukemia;   Childhood Myelodysplastic Syndromes;   Childhood Renal Cell Carcinoma;   Chronic Phase Chronic Myelogenous Leukemia;   Clear Cell Renal Cell Carcinoma;   de Novo Myelodysplastic Syndromes;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Nodal Marginal Zone B-cell Lymphoma;   Previously Treated Myelodysplastic Syndromes;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Recurrent/Refractory Childhood Hodgkin Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Hairy Cell Leukemia;   Refractory Multiple Myeloma;   Relapsing Chronic Myelogenous Leukemia;   Splenic Marginal Zone Lymphoma;   Stage III Renal Cell Cancer;   Stage IV Renal Cell Cancer;   T-cell Large Granular Lymphocyte Leukemia;   Type 1 Papillary Renal Cell Carcinoma;   Type 2 Papillary Renal Cell Carcinoma;   Waldenström Macroglobulinemia
Interventions: Drug: fludarabine phosphate;   Radiation: total-body irradiation;   Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation;   Procedure: allogeneic bone marrow transplantation;   Procedure: peripheral blood stem cell transplantation;   Biological: therapeutic allogeneic lymphocytes;   Drug: cyclosporine;   Drug: mycophenolate mofetil;   Other: pharmacological study;   Other: laboratory biomarker analysis
19 Terminated Sorafenib and Interferon Alfa in Treating Patients With Locally Advanced or Metastatic Kidney Cancer
Conditions: Clear Cell Renal Cell Carcinoma;   Papillary Renal Cell Carcinoma;   Recurrent Renal Cell Cancer;   Stage III Renal Cell Cancer;   Stage IV Renal Cell Cancer
Interventions: Drug: sorafenib tosylate;   Biological: recombinant interferon alfa;   Other: laboratory biomarker analysis
20 Recruiting Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery
Conditions: Clear Cell Renal Cell Carcinoma;   Recurrent Renal Cell Carcinoma;   Stage IV Renal Cell Cancer
Interventions: Drug: Pazopanib Hydrochloride;   Other: Placebo;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Other: Pharmacological Study

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years